Ariti S.A. Medical & Pharmaceuticals, Rhythm Pharmaceuticals Inc.

Ariti S.A of Athens, Greece, announced today a strategic partnership with Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases. Through this collaboration, Ariti will spearhead multiple initiatives aiming to raise awareness of rare melanocortin-4 receptor (MC4R) pathway diseases and their hallmark characteristics of hyperphagia – a pathological hunger that leads to abnormal food-seeking behaviors – and early onset obesity among healthcare professionals in Greece. This partnership underscores Ariti’s commitment to expanding its presence in the rare endocrinology field.